Effectiveness of Adherence to Procalcitonin-Guided Antibiotic Protocol in Patients with Severe Sepsis
DOI:
https://doi.org/10.36283/ziun-pjmd14-4/059Keywords:
Procalcitonin, Drug Resistance, MicrobialAbstract
Background:
The misuse of antibiotic therapies in hospitalized sepsis patients increases hospital length of stay and antimicrobial resistance. Procalcitonin (PCT) is a bacterial infection biomarker that can guide doctors in their decisions about whether to continue antibiotic therapy. The study aimed to compare hospital length of stay and duration of antibiotic therapy in patients managed with PCT decision protocols against comparable patients managed with standard care without PCT.
Method:
A randomized controlled trial was conducted in the Department of Medicine, MTI/Khyber Teaching Hospital, Peshawar, over six months. A total of 104 patients with severe sepsis were reviewed and randomized into two equal groups. PCT-guided antibiotic therapy was given to Group A patients while Group B patients received standard treatment without PCT. Patients were followed to discharge. Outcomes assessed were hospital length of stay and duration of antibiotic therapy. Data was analyzed using SPSS version 25, with a p ≤ 0.05 considered statistically significant.
Results: The mean length of hospital stay was shorter in the PCT-guided group (14.2 ± 4.6 days) than the standard group (18.1 ± 5.3 days; p = 0.0001). The mean length of antibiotic therapy was also reduced in Group A (7.9 ± 2.3 days) versus Group B (11.6 ± 3.1 days; p = 0.0001).
Conclusion: PCT-guided antibiotic protocol significantly reduces antibiotic exposure in addition to hospital stay for patients who present with severe sepsis. As a result, this treatment fostered antimicrobial stewardship and positively impacted clinical outcomes.
References
1. Wang W, Liu CF. Sepsis heterogeneity. World J Pediatr. 2023 Oct;19(10):919-927. doi: 10.1007/s12519-023-00689-8. Epub 2023 Feb 3. PMID: 36735197.
2. Zhu CL, Wang Y, Liu Q, Li HR, Yu CM, Li P, Deng XM, Wang JF. Dysregulation of neutrophil death in sepsis. Front Immunol. 2022 Aug 18;13:963955. doi: 10.3389/fimmu.2022.963955. PMID: 36059483; PMCID: PMC9434116.
3. La Via L, Sangiorgio G, Stefani S, Marino A, Nunnari G, Cocuzza S, La Mantia I, Cacopardo B, Stracquadanio S, Spampinato S, Lavalle S, Maniaci A. The Global Burden of Sepsis and Septic Shock. Epidemiologia (Basel). 2024 Jul 25;5(3):456-478. doi: 10.3390/epidemiologia5030032. PMID: 39189251; PMCID: PMC11348270.
4. De Waele JJ. Importance of timely and adequate source control in sepsis and septic shock. J Intensive Med. 2024 Feb 27;4(3):281-286. doi: 10.1016/j.jointm.2024.01.002. PMID: 39035625; PMCID: PMC11258501.
5. Ahmed SK, Hussein S, Qurbani K, Ibrahim RH, Fareeq A, Mahmood KA, Mohamed MG. Antimicrobial resistance: Impacts, challenges, and future prospects. Journal of Medicine, Surgery, and Public Health. 2024 Apr 1;2:100081, https://doi.org/10.1016/j.glmedi.2024.100081.
6. Xu HG, Tian M, Pan SY. Clinical utility of procalcitonin and its association with pathogenic microorganisms. Crit Rev Clin Lab Sci. 2022 Mar;59(2):93-111. doi: 10.1080/10408363.2021.1988047. Epub 2021 Oct 18. PMID: 34663176.
7. Biswas S, Rani F, Haque S, Suman D, Dixit RK, Biswas S. Procalcitonin: A revolutionary biomarker in the diagnosis and management of infections. Int J Life Sci Biotechnol Pharm Res. 2025 Feb;14(2):93. doi:10.69605/ijlbpr_14.2.2025.93.
8. Gornik I, Lapić I, Franić H, Radulović B, Miklić L, Rogić D. Unnecessary repetitions of C-reactive protein and leukocyte count at the emergency department observation unit contribute to higher hospital admission rates. Diagnosis (Berl). 2024 Sep 17;12(1):108-114. doi: 10.1515/dx-2024-0139. PMID: 39279324.
9. Llor C. C-reactive protein point-of-care testing to guide antibiotic prescribing for respiratory tract infections. Expert Rev Respir Med. 2025 Aug;19(8):863-877. doi: 10.1080/17476348.2025.2510378. Epub 2025 May 23. PMID: 40401764.
10. Perrella A, Giuliani A, De Palma M, Castriconi M, Molino C, Vennarecci G, Antropoli C, Esposito C, Calise F, Frangiosa A; Infection in Surgery Study Group AORN A. Cardarelli. C-reactive protein but not procalcitonin may predict antibiotic response and outcome in infections following major abdominal surgery. Updates Surg. 2022 Apr;74(2):765-771. doi: 10.1007/s13304-021-01172-7. Epub 2021 Oct 26. PMID: 34699035; PMCID: PMC8546392.
11. Essmann L, Wirz Y, Gregoriano C, Schuetz P. One biomarker does not fit all: tailoring anti-infective therapy through utilization of procalcitonin and other specific biomarkers. Expert Rev Mol Diagn. 2023 Jul-Dec;23(9):739-752. doi: 10.1080/14737159.2023.2242782. Epub 2023 Jul 31. PMID: 37505928.
12. Schuetz P. How to best use procalcitonin to diagnose infections and manage antibiotic treatment. Clin Chem Lab Med. 2022 Nov 2;61(5):822-828. doi: 10.1515/cclm-2022-1072. PMID: 36317790.
13. Papp M, Kiss N, Baka M, Trásy D, Zubek L, Fehérvári P, Harnos A, Turan C, Hegyi P, Molnár Z. Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta-analysis. Crit Care. 2023 Oct 13;27(1):394. doi: 10.1186/s13054-023-04677-2. PMID: 37833778; PMCID: PMC10576288.
14. Kourbeti I, Kamiliou A, Samarkos M. Antibiotic Stewardship in Surgical Departments. Antibiotics (Basel). 2024 Apr 4;13(4):329. doi: 10.3390/antibiotics13040329. PMID: 38667005; PMCID: PMC11047567.
15. Hohn A, Balfer N, Heising B, Hertel S, Wiemer JC, Hochreiter M, Schröder S. Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock. Ann Intensive Care. 2018 Jun 4;8(1):68. doi: 10.1186/s13613-018-0415-5. PMID: 29869120; PMCID: PMC5986690.
16. Duijkers R, Prins HJ, Kross M, Snijders D, van den Berg JWK, Werkman GM, van der Veen N, Schoorl M, Bonten MJM, van Werkhoven CH, Boersma WG. Biomarker guided antibiotic stewardship in community acquired pneumonia: A randomized controlled trial. PLoS One. 2024 Aug 20;19(8):e0307193. doi: 10.1371/journal.pone.0307193. PMID: 39163362; PMCID: PMC11335096.
17. Gutiérrez-Pizarraya A, León-García MDC, De Juan-Idígoras R, Garnacho-Montero J. Clinical impact of procalcitonin-based algorithms for duration of antibiotic treatment in critically ill adult patients with sepsis: a meta-analysis of randomized clinical trials. Expert Rev Anti Infect Ther. 2022 Jan;20(1):103-112. doi: 10.1080/14787210.2021.1932462. Epub 2021 Jun 4. PMID: 34027785.
18. Siriwardena AK, Jegatheeswaran S, Mason JM; PROCAP investigators. A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):913-921. doi: 10.1016/S2468-1253(22)00212-6. Epub 2022 Jul 19. PMID: 35863358.
19. Siriwardena AK, Jegatheeswaran S, Mason JM; PROCAP investigators. A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):913-921. doi: 10.1016/S2468-1253(22)00212-6. Epub 2022 Jul 19. PMID: 35863358.
20. Heilmann E, Gregoriano C, Annane D, Reinhart K, Bouadma L, Wolff M et al. Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials. Age Ageing. 2021 Sep 11;50(5):1546-1556. doi: 10.1093/ageing/afab078. PMID: 33993243; PMCID: PMC8437072.
21. Heilmann E, Gregoriano C, Annane D, Reinhart K, Bouadma L, Wolff M, Chastre J, Luyt CE, Tubach F, Branche AR, Briel M. Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials. Age and ageing. 2021 Sep;50(5):1546-56. doi: 10.1093/ageing/afab078. PMID: 33993243; PMCID: PMC8437072.
22. Chambliss AB, Patel K, Colón-Franco JM, Hayden J, Katz SE, Minejima E, Woodworth A. AACC Guidance Document on the Clinical Use of Procalcitonin. J Appl Lab Med. 2023 May 4;8(3):598-634. doi: 10.1093/jalm/jfad007. PMID: 37140163.
23. Park DW, Choi JY, Kim CJ, Kim JH, Kim HB, Lee DG. Implementation of Procalcitonin in Antibiotic Stewardship: Derivation of a Consensus Algorithm for Procalcitonin Use in Clinical Practice. Infect Chemother. 2022 Dec;54(4):621-636. doi: 10.3947/ic.2022.0170. PMID: 36596678; PMCID: PMC9840958.
24. Gavazzi G, Drevet S, Debray M, Bosson JL, Tidadini F, Paccalin M, de Wazieres B, Celarier T, Bonnefoy M, Vitrat V. Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study. BMC Geriatr. 2022 Dec 14;22(1):965. doi: 10.1186/s12877-022-03658-4. Erratum in: BMC Geriatr. 2023 Mar 30;23(1):189. doi: 10.1186/s12877-023-03818-0. PMID: 36517740; PMCID: PMC9748380.
25. Elnajdy D, El-Dahiyat F. Antibiotics duration guided by biomarkers in hospitalized adult patients; a systematic review and meta-analysis. Infect Dis (Lond). 2022 Jun;54(6):387-402. doi: 10.1080/23744235.2022.2037701. Epub 2022 Feb 17. PMID: 35175169.
Downloads
Published
Issue
Section
License
Copyright (c) 1970 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
